GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2007

Enzon Secures Supply for its Leukemia Treatment

  • Ovation Pharmaceuticals will supply the active ingredient used in the production of Enzon Pharmaceuticals’ acute lymphoblastic leukemia (ALL) treatment. Oncaspar is a form of L-asparaginase enhanced with Enzon’s PEGylation technology.

    The deal was signed after the expiration of a previous agreement between the two companies on December 31, 2006. Ovation has thus agreed to supply a sufficient quantity of L-asparaginase material through 2009. In addition, Enzon will make an upfront payment for a nonexclusive license to the cell line owned by Ovation from which the L-asparaginase material is currently sourced.

    Enzon expects to transfer manufacturing and technology involving the cell line to its own supplier by December 31, 2009 to ensure long-term availability of the L-asparaginase material.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?